Innate Pharma SA (IPHYF) — SEC Filings
Innate Pharma SA (IPHYF) — 50 SEC filings. Latest: 6-K (Dec 22, 2025). Includes 49 6-K, 1 20-F.
View Innate Pharma SA on SEC EDGAR
Overview
Innate Pharma SA (IPHYF) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 6-K filed on Dec 22, 2025: Innate Pharma SA filed a Form 6-K on December 22, 2025, reporting a press release dated December 22, 2025. The filing does not contain specific financial figures or operational details beyond the reporting of this press release.
Sentiment Summary
Across 50 filings, the sentiment breakdown is: 50 neutral. The dominant filing sentiment for Innate Pharma SA is neutral.
Filing Type Overview
Innate Pharma SA (IPHYF) has filed 49 6-K, 1 20-F with the SEC between Nov 2024 to Dec 2025.
Filings by Year
Recent SEC Filings (50)
Risk Profile
Risk Assessment: Of IPHYF's 47 recent filings, 0 were flagged as high-risk, 0 as medium-risk, and 47 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Key Executives
- Jonathan Dickinson
- Dr. Shiraj Sen
- Dr. Sonia Quaratino
- Johnathan Dickinson
- Dr Sonia Quaratino
- Dr. Michel Azoulay
Top Tags
press-release (24) · filing (20) · sec-filing (15) · foreign-private-issuer (15) · reporting (7) · 6-k (6) · regulatory-filing (6) · disclosure (5) · foreign-issuer (5) · regulatory-update (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Reporting Period End Date | 20250630 | Indicates the latest financial data available in this filing. |
| Previous Year End Date | 2023-12-31 | Provides a comparative financial snapshot from the prior year. |
| Form Type | 6-K | Standard report for foreign private issuers |
| SEC Filing Type | 6-K | Indicates a report of foreign private issuers. |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Innate Pharma SA (IPHYF)?
Innate Pharma SA has 50 recent SEC filings from Nov 2024 to Dec 2025, including 49 6-K, 1 20-F. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of IPHYF filings?
Across 50 filings, the sentiment breakdown is: 50 neutral. The dominant sentiment is neutral.
Where can I find Innate Pharma SA SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Innate Pharma SA (IPHYF) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Innate Pharma SA?
Financial highlights for Innate Pharma SA are available when 10-K or 10-Q filings are enriched with AI analysis. Check back as new filings are processed.
What is the investment thesis for IPHYF?
Investment thesis data for IPHYF will be available once enriched filings are processed.
Who are the key executives at Innate Pharma SA?
Key executives identified across Innate Pharma SA's filings include Jonathan Dickinson, Dr. Shiraj Sen, Dr. Sonia Quaratino, Johnathan Dickinson, Dr Sonia Quaratino and 1 others.
What are the main risk factors for Innate Pharma SA stock?
Of IPHYF's 47 assessed filings, 0 were flagged high-risk, 0 medium-risk, and 47 low-risk.
What are recent predictions and forward guidance from Innate Pharma SA?
Forward guidance and predictions for Innate Pharma SA are extracted from SEC filings as they are enriched.